Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 3/20 | 0.38 |
| ▸ | FAAH | O00519 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.34 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL185499 | 0.83 | TSHR (0.53) | TSHRHPGDTHRBFAAHALDH1A1 | |
| SCHEMBL29143535 | 0.81 | TSHR (0.51) | TSHRHPGDTHRBFAAHALDH1A1 | |
| Ethylene SCHEMBL28845826 | 0.81 | TSHR (0.51) | TSHRHPGDTHRBFAAHALDH1A1 | |
| SCHEMBL28568103 | 0.81 | TSHR (0.44) | TSHRHPGDALDH1A1CYP3A4MAPK1 | |
| SCHEMBL4916378 | 0.80 | TSHR (0.47) | TSHRHPGDTHRBALDH1A1CYP3A4 | |
| SCHEMBL27471012 | 0.79 | TSHR (0.53) | TSHRHPGDTHRBALDH1A1CYP3A4 | |
| SCHEMBL448883 | 0.79 | FAAH (0.42) | FAAHALDH1A1CA2CA1CNR1 | |
| SCHEMBL991328 | 0.78 | FAAH (0.50) | TSHRHPGDTHRBFAAHALDH1A1 | |
| SCHEMBL11572223 | 0.77 | TSHR (0.53) | TSHRHPGDTHRBALDH1A1CYP3A4 | |
| SCHEMBL28444211 | 0.77 | TSHR (0.47) | TSHRHPGDTHRBFAAHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557888-B2 | Polymerizable compositions with improved through-curing depth | IVOCLAR VIVADENT AG (LI) | 2013-10-15 | — | — | US | disclosed |
| US-8557888-B2 | Polymerizable compositions with improved through-curing depth | IVOCLAR VIVADENT AG (LI) | 2013-10-15 | — | — | US | disclosed |
| US-20120302657-A1 | Polymerizable compositions with improved through-curing depth | IVOCLAR VIVADENT AG (LI) | 2012-11-29 | — | — | US | disclosed |
| US-20120302657-A1 | Polymerizable compositions with improved through-curing depth | IVOCLAR VIVADENT AG (LI) | 2012-11-29 | — | — | US | disclosed |
| EP-2455059-A1 | Polymerisable compound having improved hardening depth | Ivoclar Vivadent AG (LI) | 2012-05-23 | — | — | EP | disclosed |
| US-7249723-B2 | Organic solvent dispersed nano-talc slurry | NGX, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| WO-2007024252-A2 | ORGANIC SOLVENT DISPERSED NANO-TALC SLURRY | NANOMAT, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20060086837-A1 | Dry milling talc powder, mixing the dry-milled nano-talc powder with an organic solvent andwet milling the nano-talc-solvent mix | NGX, INC. | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302657-A1 | Polymerizable compositions with improved through-curing depth | NR4A2, NR2C2, NOS2 | TSHR 3716/4885HPGD 1427/4885THRB 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.